Aclaris Therapeutics Stock Price

-0.75 (-4.17%)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aclaris Therapeutics Inc ACRS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.75 -4.17% 17.23 16:31:44
Open Price Low Price High Price Close Price Prev Close
18.10 17.19 18.21 17.23 17.98
Bid Price Ask Price Spread News
17.23 17.45 0.22 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,072 687,101 $ 17.63 $ 12,111,037 791,910 1.38 - 30.375
Last Trade Time Type Quantity Stock Price Currency
16:05:06 average 21,546 $ 17.23 USD

Aclaris Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.02B 59.15M 50.06M $ 6.48M $ - -1.20 -12.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 478.41k 4.60%

more financials information »

Aclaris Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ACRS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week18.3218.6917.1918.06747,490-1.09-5.95%
1 Month21.7324.0016.8219.43982,308-4.50-20.71%
3 Months23.7930.37516.8222.62713,457-6.56-27.57%
6 Months6.9430.3755.6519.601,828,25910.29148.27%
1 Year1.4730.3751.3815.341,227,79415.761,072.11%
3 Years19.4830.3750.709.25872,077-2.25-11.55%
5 Years18.0933.250.7011.66623,578-0.86-4.75%

Aclaris Therapeutics Description

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are ATI-450, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Your Recent History
Aclaris Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.